According to a market report by Lucintel, the future of the global ovarian cancer diagnostics market looks promising with opportunities in the cancer diagnostic center, hospital laboratory, and research institute markets. The global ovarian cancer diagnostics market is expected to reach an estimated $2 billion by 2030 at a CAGR of 6.9% from 2024 to 2030. The major drivers for this market are growing prevalence of ovarian cancer, increasing awareness towards cancer, and rising demand for improved and enhanced diagnostic processes and techniques.
A more
than 150-page report to understand trends, opportunity and forecast in global ovarian
cancer diagnostics market to 2030 by product (instruments and kits &
reagents), diagnosis type (imaging, blood test, biopsy, and others), cancer
type (epithelial tumor, germ cell, and stromal cell tumor), end use (cancer
diagnostic centers, hospital laboratories, research institutes, and others),
and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel
forecasts that imaging is expected to witness highest growth over the forecast
period due to the growing emphasis on early cancer detection and staging.
Within
this market, hospital laboratories will remain the largest segment due to
growing inflow of patient for cancer diagnosis in hospitals, rising consumer
awareness, and increasing investments in healthcare infrastructures.
Download
sample by clicking on ovarian
cancer diagnostics market.
North
America will remain the largest region over the forecast period due to
increasing incidence of ovarian cancer, surge in elderly population, and
presence of leading market players in the region.
F. Hoffmann-La
Roche, Tosoh, Luminex Corporation, Quest Diagnostics Incorporated, Thermo
Fisher Scientific, Ngenebio, Abbott, Siemens healthcare, Myriad genetics,
Bio-Rad laboratories are the major suppliers in the ovarian cancer diagnostics market.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost
visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
No comments:
Post a Comment